CVRx Q2 Earnings Call Highlights

Key Points

• CVRx lowered its 2026 outlook due to sales-force turnover, slower territory-manager productivity ramps and reimbursement challenges. Full-year revenue is now expected at $58 million–$60 million, with third-quarter revenue projected at $13.5 million–$14.5 million.
• Second-quarter revenue rose 16% to $15.7 million and gross margin improved to 87%, driven by 21% growth in U.S. revenue. However, European revenue fell 31%, and the company plans to focus on improving existing territories rather than adding sales regions for the rest of 2026.
• Medicare Advantage reimbursement remains a headwind after one major payer’s AI-based authorization process sharply reduced initial approval rates, discouraging some physicians from recommending Barostim. CVRx also disclosed a U.S. Department of Justice investigation into certain sales and marketing practices and said it is cooperating.

CVRx NASDAQ: CVRX reported second-quarter revenue growth and an improved gross margin, but lowered its full-year outlook as sales-force turnover, slower productivity ramps and reimbursement challenges with a large Medicare Advantage payer are expected to weigh on results in the second half of 2026.

The company posted second-quarter revenue of $15.7 million, up 16% from a year earlier, while gross margin rose to 87% from 84%. U.S. revenue increased 21% to $14.8 million, supported by growth in the company’s heart failure business, new accounts and awareness of its Barostim therapy. However, European revenue declined 31% to $0.9 million.

CVRx narrowed its full-year revenue expectation to between $58 million and $60 million and said it expects third-quarter revenue of $13.5 million to $14.5 million. The company also reduced its expected operating expenses for the year to $99 million to $101 million.

Sales execution drives revised outlook

President and Chief Executive Officer Kevin Hykes said the company’s commercial challenges were concentrated in particular U.S. regions that have experienced elevated turnover and less-tenured sales leadership.

CVRx ended the quarter with 56 U.S. sales territories, unchanged from the first quarter. About 60% of quota-carrying territory managers joined the company during the past 18 months, Hykes said, straining the company’s onboarding and training infrastructure and reducing the time area sales directors could devote to coaching representatives.

“The scale of the turnover, the slower pace of the territory manager productivity ramp, and the concentration of these new hires in a subset of our regions are the primary factors behind today’s guidance update,” Hykes said.

In regions with experienced leadership and limited turnover, CVRx said it continued to see strong double-digit growth under its program-development selling strategy. By contrast, Hykes said regions with the highest turnover—more than 50% in some cases—and the least-tenured leaders have experienced negative implant growth year to date.

The company does not anticipate adding U.S. sales territories during the remainder of 2026, Chief Financial Officer Jared Oasheim said. CVRx plans instead to focus on improving productivity in existing territories and driving deeper adoption at active implanting centers.

CVRx had 258 active implanting centers at June 30, compared with 240 a year earlier. Management said net center growth is unlikely for the balance of the year because new center activations have historically accompanied new territory launches, while the company also continues to sunset lower-volume “dabbling” accounts.

Training and field support initiatives

To address commercial execution issues, CVRx is refining its hiring profiles, expanding onboarding and training resources, and extending its development process. The company said the program will now include an additional three months of hands-on field mentorship following an initial three-month didactic phase.

The company is also creating field-based reimbursement and business-management roles intended to free area sales directors to spend more time coaching territory managers. It has added two vice president-level leadership positions to support area sales directors.

Hykes said the new roles will be funded through resource reallocation rather than incremental spending. Oasheim said lower operating-expense guidance reflects both reduced revenue expectations and intentional spending reductions in marketing and development projects, with some resources redirected toward sales training and leadership support.

CVRx also moved Chief Marketing Officer Paul Verrastro into a new role supporting field teams directly. Patrick Lyon, who joined the marketing organization in the fourth quarter of 2025, was promoted to lead marketing. The company additionally named Matt Klein as vice president of legal and said it continues to search for a successor to Oasheim as CFO.

Medicare Advantage reimbursement remains uneven

Hykes said reimbursement trends outside one major Medicare Advantage payer continue to improve, but that payer’s adoption of artificial intelligence-based prior-authorization tools in February has led to more initial denials tied to administrative omissions.

The payer’s 30-day approval rate fell to roughly 25% in February and March from nearly 80% previously, according to Hykes. CVRx’s own AI tools helped raise that rate to about 40%, but the company said the rate subsequently dropped below 30% after the payer introduced additional denial tactics.

CVRx said the longer wait times and lower initial approval rate have made some physicians more hesitant to recommend Barostim therapy for patients covered by that plan. The company said it intends to appeal every denial through all stages, including administrative law review when needed.

Overall, the company reported a 60% 30-day Medicare Advantage prior-authorization approval rate in the second quarter, compared with 44% in 2025. Humana’s written coverage policy has supported that improvement, with approval rates above 90%, Hykes said.

• Traditional Medicare paid approximately 96% of submitted Barostim procedure claims across all seven Medicare administrative contractors.
• CMS proposed maintaining Barostim in new technology APC 1580, with outpatient payment of approximately $45,000 per procedure for 2027.
• The final inpatient payment rule raised the procedure’s payment rate from $43,000 to $45,000, effective Oct. 1.

Financial results, clinical programs and cash position

Second-quarter gross profit increased 20% to $13.7 million. Research and development expense rose $0.7 million to $3.1 million, primarily due to headcount and clinical-trial costs. Selling, general and administrative expense increased 1% to $23.6 million, reflecting higher stock-based compensation and legal expenses, partly offset by lower advertising and travel expenses.

CVRx reported a net loss of $14 million, or $0.53 per share, compared with a loss of $14.7 million, or $0.57 per share, a year earlier. Cash and cash equivalents totaled $64.6 million at June 30. Oasheim said management believes the company has at least 18 months of cash available and retains $40 million of undrawn capacity under its debt facility.

The company said its BENEFIT-HF trial is ahead of internal expectations for center activations and patient enrollment. CVRx is also increasing investment in real-world evidence datasets, with initial publications expected this fall. Hykes said those data could potentially support an expanded indication and label through the FDA’s real-world evidence pathway.

Separately, Hykes disclosed that CVRx received a civil investigative demand from the U.S. Department of Justice in May related to certain sales and marketing practices. He said the company is fully cooperating with the investigation.

About CVRx (NASDAQ:CVRX)

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company's flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body's natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source